How much revenue does Bafna Pharmaceuticals make?

Bafna Pharmaceuticals reported 1.46 billion INR in revenue for fiscal year 2025, down 4.3% from 1.52 billion INR in fiscal year 2024. In Q3 2026 revenue was 382.86 million INR.

Where does Bafna Pharmaceuticals make most of its revenue?

Export: 50% of revenue by region in fiscal year 2025, followed by India (50%).

What companies are similar to Bafna Pharmaceuticals?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Jagsonpal Pharmaceuticals Limited (JAGSNPHARM.NS), Bharat Parenterals Ltd (BPLPHARMA.BO), Lincoln Pharmaceuticals Limited (LINCOLN.NS), Themis Medicare Limited (THEMISMED.NS).

Bafna Pharmaceuticals Limited (BAFNAPH.NS) Stock

About Bafna Pharmaceuticals Limited

Bafna Pharmaceuticals Limited manufactures and sells finished pharmaceutical formulations in India. The company offers its products in various dosage forms, including tablets, capsules, and solid orals. It provides various products for cardiovascular and hypertension, potent oncology, anti-infectives, central nervous system, and diabetic related diseases, as well as provision of contract research ...

At a glance

Bafna Pharmaceuticals reported revenue of 1.46 billion INR for fiscal year 2025, down 4.3% from fiscal year 2024, and net income of 41.53 million INR. In Q3 2026 (the quarter ended December 31, 2025) revenue was 382.86 million INR, up 15.4% from a year before. Export was its largest region in fiscal year 2025, with 50% of revenue.

Figures from company filings; latest fiscal year ended March 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.